Vanguard Group Inc. Sells 326,415 Shares of AnaptysBio, Inc. $ANAB

Vanguard Group Inc. reduced its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 17.7% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,517,325 shares of the biotechnology company’s stock after selling 326,415 shares during the period. Vanguard Group Inc. owned 5.13% of AnaptysBio worth $28,207,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. US Bancorp DE grew its holdings in AnaptysBio by 126.5% during the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 979 shares during the period. Farther Finance Advisors LLC lifted its position in AnaptysBio by 9,778.9% in the 1st quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 1,858 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in AnaptysBio by 131.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 1,531 shares in the last quarter. GAMMA Investing LLC purchased a new position in AnaptysBio in the first quarter worth $113,000. Finally, California State Teachers Retirement System increased its position in shares of AnaptysBio by 10.3% during the 4th quarter. California State Teachers Retirement System now owns 14,590 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 1,359 shares during the last quarter.

AnaptysBio Stock Up 2.2%

NASDAQ ANAB opened at $20.40 on Thursday. AnaptysBio, Inc. has a twelve month low of $12.21 and a twelve month high of $40.70. The firm has a market capitalization of $571.20 million, a PE ratio of -4.55 and a beta of -0.20. The stock’s 50 day moving average is $23.43 and its 200 day moving average is $20.75.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) EPS for the quarter, topping analysts’ consensus estimates of ($1.50) by $0.16. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%.The firm had revenue of $22.26 million for the quarter, compared to analysts’ expectations of $11.55 million. On average, research analysts anticipate that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

Insider Buying and Selling

In other AnaptysBio news, Director Hollings Renton sold 20,925 shares of the business’s stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $23.57, for a total value of $493,202.25. Following the sale, the director directly owned 4,965 shares of the company’s stock, valued at approximately $117,025.05. The trade was a 80.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 33.50% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ANAB shares. Guggenheim restated a “buy” rating and set a $90.00 price target (up previously from $54.00) on shares of AnaptysBio in a research note on Wednesday, May 28th. Wedbush raised their target price on AnaptysBio from $40.00 to $45.00 and gave the stock an “outperform” rating in a research note on Thursday, August 7th. JPMorgan Chase & Co. raised their target price on AnaptysBio from $42.00 to $80.00 and gave the stock an “overweight” rating in a research note on Thursday, July 24th. HC Wainwright raised shares of AnaptysBio from a “neutral” rating to a “buy” rating and upped their price target for the stock from $22.00 to $38.00 in a report on Wednesday, June 4th. Finally, UBS Group reissued a “neutral” rating and issued a $20.00 target price (up previously from $18.00) on shares of AnaptysBio in a research note on Tuesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $46.13.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.